Home > Archive > 2011 >

Volume 30, Number 2 (May/June)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Type 2 Diabetes (pages 6-14)

Muhammad A. Abdul-Ghani, M.D., Ph.D., and Ralph A. DeFronzo, M.D.

SGLT2 inhibitors have been shown to reduce plasma glucose concentration without hypoglycemia and promote weight loss. Drs. Abdul-Ghani and DeFronzo explore the mechanism of action of this new class of antidiabetic agent and offer a thorough review of studies into its effects on glucose levels and body weight.
Drug treatmentSodium-glucose cotransporter 2 inhibitors

Alternatives to the Sleep Lab (pages 15-20)

Liz Seegert, M.A.

Up to a quarter of patients with diabetes have obstructive sleep apnea. Although in-lab sleep testing with polysomnography remains the gold standard of diagnosis, home sleep apnea tests are increasingly seen as a reliable and less costly alternative. Ms. Seegert explains the various sleep testing options, examines issues related to reimbursement and physician certification, and reviews studies of four popular home sleep testing devices.
Complications and comorbiditiesSleep disorders

Diabetes Self-Management in the Heat (pages 21-24)

Sydney A. Westphal, M.D., Adrienne A. Nassar, M.D., Raymond D. Childs, C.N.P., N.P., Karen M. Seifert, M.S.N, R.N., C.D.E., Mary E. Boyle, C.N.P., N.P., Margaret Fowke, M.A., Paul Iñiguez, B.S., M.A., and Curtiss B. Cook, M.D.

Hot weather can present multiple challenges for diabetes patients, including a higher risk of heat exhaustion, dehydration, and unpredictable blood glucose levels. In addition, many diabetes medicines and devices may be at risk at temperatures common in summer months. The authors offer clear advice on helping your patients manage their diabetes, and protect their diabetes medications and supplies, when the temperature rises.
Management strategies and tools
EducationSelf-management strategies

Pioglitazone for Diabetes Prevention? (pages 26)

Charles A. Reasner, M.D.

A recent study published in The New England Journal of Medicine tested pioglitazone’s ability to prevent diabetes in patients with impaired glucose tolerance. The Editor reviews the results of the study and considers the potential benefits and risk of using pioglitazone for diabetes prevention.
Drug treatmentThiazolidinediones

Troubleshooting Continuous Glucose Monitoring Systems (pages 27-30)

Neesha Ramchandani, P.N.P., C.D.E.

Despite their many benefits, continuous glucose monitors often frustrate patients. Ms. Ramchandani identifies questions you are likely to receive from your patients about continuous glucose monitoring and provides practical, patient-directed answers.
EquipmentContinuous glucose monitoring systems